Basel Medical Group Ltd (NASDAQ:BMGL) Stock Short Interest Falls 92.9%

Basel Medical Group Ltd (NASDAQ:BMGL) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 11,310 shares, a decline of 92.9% from the September 15th total of 159,585 shares. Based on an average trading volume of 57,193 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Basel Medical Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Basel Medical Group Price Performance

NASDAQ:BMGL traded up $0.15 during trading hours on Friday, hitting $3.75. 104,006 shares of the company’s stock traded hands, compared to its average volume of 199,723. Basel Medical Group has a 52 week low of $2.56 and a 52 week high of $21.72. The business’s fifty day simple moving average is $4.67 and its two-hundred day simple moving average is $6.26.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.